Multicenter clinical evaluation of the portrait toxigenic C. difficile assay for detection of toxigenic Clostridium difficile strains in clinical stool specimens

Blake W. Buchan, Tami Lea A. Mackey, Judy A. Daly, Garrison Alger, Gerald Denys, Lance R. Peterson, Sue C. Kehl, Nathan A. Ledeboer

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

We compared the Portrait Toxigenic C. difficile Assay, a new semiautomated sample-to-result molecular test, to a toxigenic bacterial culture/cell cytotoxin neutralization assay (TBC/CCNA) for the detection of toxigenic Clostridium difficile in 549 stool specimens. Stool specimens were also tested by one of three alternative FDA-cleared molecular tests for toxigenic C. difficile (Xpert C. difficile, Illumigene C. difficile, or GeneOhm Cdiff). The sensitivities and specificities of the molecular tests compared to TBC/CCNA were as follows: 98.2% and 92.8% for the Portrait assay, 100% and 91.7% for the Xpert assay, 93.3% and 95.1% for the Illumigene assay, and 97.4% and 98.5% for the GeneOhm assay, respectively. The majority of Portrait false-positive results (20/31; 64.5%) were also positive for C. difficile by an alternative molecular test, suggesting an increased sensitivity compared to the culture-based "gold standard" method. The Portrait test detected an assay input of 30 CFU in 100% of spiked samples and detected an input of 10 CFU in 96.7% of samples tested.

Original languageEnglish (US)
Pages (from-to)3932-3936
Number of pages5
JournalJournal of clinical microbiology
Volume50
Issue number12
DOIs
StatePublished - Dec 1 2012

Fingerprint

Clostridium difficile
Cytotoxins
Cell Culture Techniques
Sensitivity and Specificity

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Multicenter clinical evaluation of the portrait toxigenic C. difficile assay for detection of toxigenic Clostridium difficile strains in clinical stool specimens. / Buchan, Blake W.; Mackey, Tami Lea A.; Daly, Judy A.; Alger, Garrison; Denys, Gerald; Peterson, Lance R.; Kehl, Sue C.; Ledeboer, Nathan A.

In: Journal of clinical microbiology, Vol. 50, No. 12, 01.12.2012, p. 3932-3936.

Research output: Contribution to journalArticle

Buchan, Blake W. ; Mackey, Tami Lea A. ; Daly, Judy A. ; Alger, Garrison ; Denys, Gerald ; Peterson, Lance R. ; Kehl, Sue C. ; Ledeboer, Nathan A. / Multicenter clinical evaluation of the portrait toxigenic C. difficile assay for detection of toxigenic Clostridium difficile strains in clinical stool specimens. In: Journal of clinical microbiology. 2012 ; Vol. 50, No. 12. pp. 3932-3936.
@article{cecf8e9660124c0bb96bdf468b3c0156,
title = "Multicenter clinical evaluation of the portrait toxigenic C. difficile assay for detection of toxigenic Clostridium difficile strains in clinical stool specimens",
abstract = "We compared the Portrait Toxigenic C. difficile Assay, a new semiautomated sample-to-result molecular test, to a toxigenic bacterial culture/cell cytotoxin neutralization assay (TBC/CCNA) for the detection of toxigenic Clostridium difficile in 549 stool specimens. Stool specimens were also tested by one of three alternative FDA-cleared molecular tests for toxigenic C. difficile (Xpert C. difficile, Illumigene C. difficile, or GeneOhm Cdiff). The sensitivities and specificities of the molecular tests compared to TBC/CCNA were as follows: 98.2{\%} and 92.8{\%} for the Portrait assay, 100{\%} and 91.7{\%} for the Xpert assay, 93.3{\%} and 95.1{\%} for the Illumigene assay, and 97.4{\%} and 98.5{\%} for the GeneOhm assay, respectively. The majority of Portrait false-positive results (20/31; 64.5{\%}) were also positive for C. difficile by an alternative molecular test, suggesting an increased sensitivity compared to the culture-based {"}gold standard{"} method. The Portrait test detected an assay input of 30 CFU in 100{\%} of spiked samples and detected an input of 10 CFU in 96.7{\%} of samples tested.",
author = "Buchan, {Blake W.} and Mackey, {Tami Lea A.} and Daly, {Judy A.} and Garrison Alger and Gerald Denys and Peterson, {Lance R.} and Kehl, {Sue C.} and Ledeboer, {Nathan A.}",
year = "2012",
month = "12",
day = "1",
doi = "10.1128/JCM.02083-12",
language = "English (US)",
volume = "50",
pages = "3932--3936",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "12",

}

TY - JOUR

T1 - Multicenter clinical evaluation of the portrait toxigenic C. difficile assay for detection of toxigenic Clostridium difficile strains in clinical stool specimens

AU - Buchan, Blake W.

AU - Mackey, Tami Lea A.

AU - Daly, Judy A.

AU - Alger, Garrison

AU - Denys, Gerald

AU - Peterson, Lance R.

AU - Kehl, Sue C.

AU - Ledeboer, Nathan A.

PY - 2012/12/1

Y1 - 2012/12/1

N2 - We compared the Portrait Toxigenic C. difficile Assay, a new semiautomated sample-to-result molecular test, to a toxigenic bacterial culture/cell cytotoxin neutralization assay (TBC/CCNA) for the detection of toxigenic Clostridium difficile in 549 stool specimens. Stool specimens were also tested by one of three alternative FDA-cleared molecular tests for toxigenic C. difficile (Xpert C. difficile, Illumigene C. difficile, or GeneOhm Cdiff). The sensitivities and specificities of the molecular tests compared to TBC/CCNA were as follows: 98.2% and 92.8% for the Portrait assay, 100% and 91.7% for the Xpert assay, 93.3% and 95.1% for the Illumigene assay, and 97.4% and 98.5% for the GeneOhm assay, respectively. The majority of Portrait false-positive results (20/31; 64.5%) were also positive for C. difficile by an alternative molecular test, suggesting an increased sensitivity compared to the culture-based "gold standard" method. The Portrait test detected an assay input of 30 CFU in 100% of spiked samples and detected an input of 10 CFU in 96.7% of samples tested.

AB - We compared the Portrait Toxigenic C. difficile Assay, a new semiautomated sample-to-result molecular test, to a toxigenic bacterial culture/cell cytotoxin neutralization assay (TBC/CCNA) for the detection of toxigenic Clostridium difficile in 549 stool specimens. Stool specimens were also tested by one of three alternative FDA-cleared molecular tests for toxigenic C. difficile (Xpert C. difficile, Illumigene C. difficile, or GeneOhm Cdiff). The sensitivities and specificities of the molecular tests compared to TBC/CCNA were as follows: 98.2% and 92.8% for the Portrait assay, 100% and 91.7% for the Xpert assay, 93.3% and 95.1% for the Illumigene assay, and 97.4% and 98.5% for the GeneOhm assay, respectively. The majority of Portrait false-positive results (20/31; 64.5%) were also positive for C. difficile by an alternative molecular test, suggesting an increased sensitivity compared to the culture-based "gold standard" method. The Portrait test detected an assay input of 30 CFU in 100% of spiked samples and detected an input of 10 CFU in 96.7% of samples tested.

UR - http://www.scopus.com/inward/record.url?scp=84869217890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869217890&partnerID=8YFLogxK

U2 - 10.1128/JCM.02083-12

DO - 10.1128/JCM.02083-12

M3 - Article

C2 - 23015667

AN - SCOPUS:84869217890

VL - 50

SP - 3932

EP - 3936

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 12

ER -